Neurocrine Biosciences (NBIX) Net Cash Flow Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -117.27% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -167.84% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -290.21% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 270.63% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -367.42% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -7.60% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 272.00% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | 31.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.60% |
| Mar 31, 2026 | -1,047.81% |
| Dec 31, 2025 | 421.93% |
| Sep 30, 2025 | -63.46% |
| Jun 30, 2025 | 127.16% |
| Mar 31, 2025 | -126.79% |
| Dec 31, 2024 | -169.93% |
| Sep 30, 2024 | 56.63% |
| Jun 30, 2024 | -553.36% |
| Mar 31, 2024 | 191.26% |
| Dec 31, 2023 | -182.50% |
| Sep 30, 2023 | 173.01% |
| Jun 30, 2023 | 152.95% |
| Mar 31, 2023 | -141.06% |
| Dec 31, 2022 | 75.08% |
| Sep 30, 2022 | 185.94% |
| Jun 30, 2022 | -794.16% |
| Mar 31, 2022 | -139.88% |
| Dec 31, 2021 | 112.47% |
| Sep 30, 2021 | -657.84% |